<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The study characterises canine adipose-derived stem cells (cASCs) in comparison to human ASCs (hASCs) and tests their safety in a canine model after intravenous administration. cASCs from two dogs were cultured under hypoxic conditions in a medium supplemented with autologous serum. They were plastic adherent, spindle-shaped cells that expressed CD73, CD90, and CD44 but lacked CD45, CD14, HLA-DR, and CD34. cASCs differentiated toward adipogenic, osteogenic, and chondrogenic lineages, although adipogenic differentiation capacity was low. Blast transformation reaction demonstrated that these cells significantly suppress T-cell proliferation, and this ability is dose-dependent. Intravenous administration of a cell freezing medium, therapeutic dose of cASCs (2 × 10<sup>6</sup> live cells/kg), and five times higher dose of cASCs showed no significant side effects in two dogs. Microscopic tissue lesions were limited to only mild, non-specific changes. There were no signs of malignancy. The results of the study indicate that cASCs are similar to hASCs and are safe for therapeutic applications in a canine model. The proposed methodology for ASC preparation on a non-routine basis, which includes individually optimised cell culture conditions and offers risk-adapted treatment, could be used for future personalised off-the-shelf therapies, for example, in myocardial infarction or stroke.</p></abstract>

The study characterises canine adipose-derived stem cells (cASCs) in comparison to human ASCs (hASCs) and tests their safety in a canine model after intravenous administration. cASCs from two dogs were cultured under hypoxic conditions in a medium supplemented with autologous serum. They were plastic adherent, spindle-shaped cells that expressed CD73, CD90, and CD44 but lacked CD45, CD14, HLA-DR, and CD34. cASCs differentiated toward adipogenic, osteogenic, and chondrogenic lineages, although adipogenic differentiation capacity was low. Blast transformation reaction demonstrated that these cells significantly suppress T-cell proliferation, and this ability is dose-dependent. Intravenous administration of a cell freezing medium, therapeutic dose of cASCs (2 × 106 live cells/kg), and five times higher dose of cASCs showed no significant side effects in two dogs. Microscopic tissue lesions were limited to only mild, non-specific changes. There were no signs of malignancy. The results of the study indicate that cASCs are similar to hASCs and are safe for therapeutic applications in a canine model. The proposed methodology for ASC preparation on a non-routine basis, which includes individually optimised cell culture conditions and offers risk-adapted treatment, could be used for future personalised off-the-shelf therapies, for example, in myocardial infarction or stroke.

Characterisation and <italic>In Vivo</italic> Safety of Canine Adipose-Derived Stem Cells

Latvian Biomedical Research and Study Centre

Children’s Clinical University Hospital

Augusts Kirhenšteins Institute of Microbiology and Virology

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Characterisation and  Safety of Canine Adipose-Derived Stem Cells

The study characterises canine adipose-derived stem cells (cASCs) in comparison to human ASCs (hASCs) and tests their safety in a canine model after...

Characterisation and In Vivo Safety of Canine Adipose-Derived Stem Cells

Publié en ligne: 21 juin 2018

Pages: 160 - 171

Reçu: 25 sept. 2017

Accepté: 10 nov. 2017

DOI: https://doi.org/10.2478/prolas-2018-0004

Mots clés
autologous adipose-derived stem cells, stem cell safety, pulmonary first-pass effect, advanced therapy medicinal products, hospital exemption

© 2018 Uldis Bērziņš et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Characterisation and In Vivo Safety of Canine Adipose-Derived Stem Cells

Publié en ligne: 21 juin 2018

Pages: 160 - 171

Reçu: 25 sept. 2017

Accepté: 10 nov. 2017

DOI: https://doi.org/10.2478/prolas-2018-0004

Mots clésautologous adipose-derived stem cells, stem cell safety, pulmonary first-pass effect, advanced therapy medicinal products, hospital exemption

© 2018 Uldis Bērziņš et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
autologous adipose-derived stem cells, stem cell safety, pulmonary first-pass effect, advanced therapy medicinal products, hospital exemption